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The expression of the Adenovirus serotype 2 or serotype 5 (Ad2/5) E1A gene in tumor cells upregulates
ligands that are recognized by the NKG2D activating receptor, which is expressed on NK cells and T cells,
and reduces their tumorigenicity, a process dependent on NK cells and T cells. In some model systems,
the forced overexpression of NKG2D ligands on tumor cells induced antigen-speciﬁc CD8þ T cells that
mediated anti-tumor immunity. We wanted to determine if the interaction of NKG2D ligands on tumor
cells that express E1A with NKG2D on immune cells contributed to the ability of E1A to induce a CD8þ T
cell anti-tumor response or reduce tumorigenicity. To address these questions, we used the MCA-205
tumor cell line or MCA-205 cells that expressed Ad5 E1A (MCA-205-E1A cells), a fusion protein of E1A
and ovalbumin (MCA-205-E1A-OVA) or OVA (MCA-205-OVA). We found that the expression of E1A or
E1A–OVA, but not OVA, upregulated the expression of the NKG2D ligand RAE-1 on the surface of MCA-
205 cells. Additionally, MCA-205-E1A cells and MCA-205-E1A-OVA cells were more sensitive to NK cell
lysis than MCA-205 or MCA-205-OVA cells in WT B6 mice, but not NKG2D deﬁcient B6 mice. Next, we
adoptively transferred WT or NKG2D deﬁcient OT-1 T cells (CD8 T cells that recognize OVA residues 257–
264) into WT B6 mice or B6 mice that were deﬁcient in NKG2D respectively and measured the expansion
of OT-1 cells following immunization with MCA-205-E1A-OVA or MCA-205-OVA cells. We found that the
expansion of OT-1 cells following immunization of either OVA-expressing MCA-205 cell lines was not
affected by the presence or absence of NKG2D in B6 mice. Finally, we found that the capacity of E1A to
reduce the tumorigenicity of MCA-205 cells was not impaired in B6-NKG2D deﬁcient mice as compared
to WT B6 mice. Our results suggest that the ability of E1A to reduce the tumorigenicity of MCA-205 cells,
or induce an antigen-speciﬁc CD8þ T cell response, is independent of the interaction of NKG2D ligands
with the NKG2D receptor.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
NKG2D is an activating receptor found primarily on NK cells
and CD8þ T cells in rodents and humans [1]. The NKG2D ligands
are a diverse group of proteins, which are upregulated in response
to cellular stress, viral infection, cellular transformation, and DNA
damage [2–6]. The engagement of NKG2D on NK cells with NKG2D
ligands on the cell surface of target cells, leads to target cell killingB.V. This is an open access article u
; NKG2D, natural killer group
natural killer; WT, wildtype;
50, tumor producing dose 50
, 9000 W. Wisconsin Avenue,
r),and cytokine production by NK cells [1,3]. Ectopic expression of
NKG2D ligands on tumor cell surfaces has been shown to sig-
niﬁcantly reduce the tumorigenicity of tumor cells in an NK cell
dependent-manner [3,6–8]. In some tumor models, it appears that
the ectopic expression of NKG2D ligands also induces antigen-
speciﬁc, CD8þ anti-tumor immune responses [8]. How the inter-
action of NKG2D on CD8 T cells and NKG2D on target cells acti-
vates naïve CD8 T cells is unclear, as NKG2D does not appear to be
able to directly activate CD8 T cells, but instead provides co-sti-
mulatory signals [4,9–11].
Adenovirus serotype 2 or serotype 5 (Ad2/5) E1A (heretofore
referred to as E1A), when stably expressed in tumor cells, reduces
their tumorigenicity [12,13]. Both NK cells and T cells [14] mediate
the reduction of tumorigenicity by E1A. Tumor cells stably ex-
pressing E1A are sensitive to NK mediated killing in vitro and
in vivo, in part through the upregulation of NKG2D ligands [7]. Innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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increase the expression of the NKG2D ligands, RAE-1. In
B6-RAG/ mice lacking adaptive immune systems, blocking the
interaction of NKG2D ligands with the NKG2D receptor, using a
speciﬁc mAb, inhibited the lysis of MCA-205-E1A tumor cells in
vitro and increased their tumorigenicity in vivo [7].
The purpose of this study was to determine if the interaction of
NKG2D ligands on MCA-205 tumor cells that express E1A with
NKG2D on immune cells contributed to the ability of E1A to induce
an antigen-speciﬁc CD8þ T cell response. Furthermore, we sought
to determine if the upregulation of RAE-1 by E1A decreased the
tumorigenicity of MCA-205-E1A cells in WT mice. We found that
NKG2D–NKG2D ligand interactions were dispensable for the ex-
pansion of antigen-speciﬁc CD8þ T cells and for the anti-tu-
morigenic activity of E1A in WT B6 mice.Fig. 1. Stable expression of E1A–OVA fusion protein in MCA-205 cells induced RAE1
expression and sensitized cells to NKG2D-dependent NK lysis. (A) Surface expres-
sion of RAE1 on MCA-205 cells stably transfected with E1A, OVA, or E1A–OVA was
detected by ﬂow cytometry. Representative histograms show the intensity of RAE1
staining. (B, C) MCA-205-E1A and MCA-205 cells (B) or MCA-205-E1A-OVA and
MCA-205-OVA cells (C) were incubated with IL-2 activated B6 WT (solid) or NKG2D
deﬁcient (hashed) NK cells in a 5 h NK cytolysis assay and the speciﬁc lysis was
determined. Data shown is the mean7SEM from three independent experiments.
Data were analyzed by ANOVA followed by Tukey's HSD post hoc analyses. *
po0.05 and **po0.01.2. Results
2.1. Role of interaction of NKG2D ligands and the NKG2D receptor in
the NK cell lysis of E1A-expressing MCA-205 tumor cells
We previously demonstrated that the expression of E1A in the
B6-derived tumor cell line, MCA-205 cells (MCA-205-E1A), upre-
gulated the NKG2D ligand RAE1 and sensitized MCA-205 cells to
NK-mediated killing [7]. First, we generated MCA-205 cell lines
that expressed a slightly truncated OVA3-383 protein (MCA-205-
OVA) or a fusion protein of E1A and OVA3-383 (MCA-205-E1A-OVA)
[16]. Next, we determined if expression of E1A–OVA fusion protein
induced the NKG2D ligand, RAE1 on the MCA-205 cells as well. We
found that expression of E1A–OVA and E1A, but not OVA, induced
expression of RAE1 in MCA-205 cells (Fig. 1A). Next, we de-
termined if NKG2D deﬁcient NK cells, compared to normal B6 NK
cells, were impaired in their ability to kill MCA-205-E1A or MCA-
205-E1A-OVA tumor cells in a 5 h in vitro NK killing assay. These
results demonstrated that, in comparison to normal NK cells,
NKG2D deﬁcient NK cells were markedly impaired in their capa-
city to lyse both MCA-205-E1A (Fig. 1B) and MC-205-E1A-OVA
cells (C). In fact, the ability of E1A or E1A–OVA to sensitize MCA-
205 cells to NK cell killing was nearly lost when using NKG2D
deﬁcient NK cells as effector cells (Fig. 1B and C). Collectively, these
data showed that the ability of E1A or E1A–OVA to sensitize MCA-
205 cells was largely dependent on the interaction between
NKG2D on NK cells and RAE-1 on MCA-205 cells.
2.2. Role of the interaction of NKG2D ligands and the NKG2D re-
ceptor in the induction of antigen speciﬁc CD8þ T cells
We next asked if the interaction of NKG2D ligands on MCA-
205-OVA cells or MCA-205-E1A OVA cells with NKG2D on immune
cells was required for the expansion of OVA-speciﬁc CD8þ T cells.
To answer this question, we adoptively transferred NKG2D sufﬁ-
cient OT-1 cells or NKG2D deﬁcient OT-I CD8þ T cells into B6 WT
or NKG2D deﬁcient B6 mice, respectively. Twenty-four hours after
adoptive transfer of OT-1 cells, we injected MCA-205-OVA cells or
MCA-205-E1A-OVA cells into the hock of B6 WT or NKG2D deﬁ-
cient B6 mice. After 5 days, the draining lymph nodes were re-
moved, and OT-1 CD8 T cells were enumerated by ﬂow cytometry
(Fig. 1A and B). We found that the expansion of OT-1 cells fol-
lowing immunization of E1A–OVA or OVA-expressing MCA-205
cell lines was not affected by the presence or absence of NKG2D in
B6 mice. Interestingly, immunization of WT or NKG2D deﬁcient
mice with MCA-205-OVA cells, which express little RAE-1, con-
sistently led to a more robust expansion of OT-1 T cells compared
to immunization with MCA-205-E1A-OVA (Fig. 2B). The mechan-
ism for this result is under current investigation and is outside thegoals of the current manuscript.
2.3. Role of interaction of NKG2D with NKG2D ligands in mediating
tumor rejection of MCA-205 cells that express E1A or E1A–OVA
In previous studies using T cell deﬁcient, B6-Rag / mice, we
demonstrated that NK cells contribute to the rejection of MCA-
205-E1A cells in an NKG2D–NKG2D ligand dependent manner [7].
Using this ﬁnding, we next addressed the role of NKG2D–NKG2D
ligand interactions in the rejection of MCA-205 cells that express
E1A in WT (T cell sufﬁcient) mice or mice deﬁcient in NKG2D
(Fig. 3).
Tumorigenicity was measured by determining the tumor-pro-
ducing dose 50 (TPD50), which is the log10 of the number of tumor
cells required to form tumors in half of the B6 mice (Material and
methods). In previous studies, we demonstrated that the TPD50 of
MCA-205-E1A cells and MCA-205-E1A-OVA cells were equivalent
Fig. 2. NKG2D deﬁciency does not alter the expansion of OT-1 CD8 T cells in re-
sponse to injection of MCA-205-E1A-OVA cells in vivo. B6 or NKG2D deﬁcient mice
were adoptively transferred with 1105 CD45.1þ OT-1 cells that were NKG2D
sufﬁcient or NKG2D deﬁcient respectively and 24 h later administered MCA-205,
MCA-205-OVA or MCA-205-E1A-OVA tumor cells s.c. in the ﬂank. Five days later
the draining lymph node was examined by ﬂow cytometry for the percentage of
OT-1 cells (A) and the total number of OT-1 cells (B). OT-1 cells were identiﬁed as
CD45.1þ CD3þCD8þ cells. Data shown is the mean7SEM from two experiments,
with three to six mice per group. Data were analyzed by ANOVA followed by Tu-
key’s HSD post hoc analyses.
Fig. 3. NKG2D deﬁciency does not alter the tumorigenicity of MCA-205-E1A cells.
Serial log dilutions of MCA-205 cells from 1102–1105 cells or MCA-205-E1A
cells from 1105–1107 cells (3 mice/dose tumor cells) were injected s.c. into the
ﬂank of either WT B6 or NKG2D deﬁcient mice. The TPD50 was calculated 12 weeks
later. Data shown is the mean7SEM from two experiments. Data were analyzed by
a Student's t-test. * po0.01.
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upregulate RAE-1 expression or sensitize MCA-205 cells to NK cell
lysis was also equivalent (Fig. 1A–C). Therefore, to decrease the
numbers of mice, only MCA-205 cells and MCA-205-E1A cells
were used in these tumor induction studies. We found that the
TPD50 of MCA-205-E1A cells were equivalent in WT B6 mice
compared to mice that lacked NKG2D. Collectively, these studies
suggest that NKG2D–NKG2D ligand interactions play a relatively
minor role in the ability of E1A to reduce tumorigenicity in WT (T
cell sufﬁcient) mice.3. Discussion
In this study, we investigated the role of the interaction of
NKG2D ligands on tumor cells that express E1A and NKG2D on
immune cells in elicitation of antigen-speciﬁc CD8þ T cells, and
the anti-tumorigenic properties of E1A. Prior studies have shownthat the reduction of tumorigenicity by E1A is dependent on NK
cells and T cells [14]. Expression of E1A induces NKG2D ligands on
the surface of cells, and NKG2D is expressed on NK cells and CD8þ
T cells. The NK cell mediated killing of tumor cells that express E1A
is dependent, at least in part, on the interaction between NKG2D–
NKG2D ligands [7]. Therefore, it seemed possible that the inter-
action of NKG2D ligands with NKG2D could link the innate and
CD8þ T cell response to E1A expressing tumor cells in mice.
We found that the expression of E1A, or a fusion protein of E1A
and OVA, induced the expression of RAE-1 on MCA-205 cells
(Fig. 1A). Furthermore, the lysis of MCA-205-E1A cells or MCA-
205-E1A-OVA cells by NKG2D deﬁcient NK cells was signiﬁcantly
decreased compared to NKG2D sufﬁcient NK cells (Fig. 1B). These
results are consistent with our prior studies and the large litera-
ture on the importance of the interaction of NKG2D ligands and
NKG2D in the NK cell mediated lysis of speciﬁc target cells that
express high levels of NKG2D ligands.
In contrast to NK cell mediated killing of tumor cells that ex-
press E1A, we found that the interaction of NKG2D ligands with
NKG2D was dispensable for the expansion of OVA-speciﬁc CD8þ T
cells following challenge with MCA-205-OVA cells or MCA-205-
E1A-OVA cells (Fig. 2). Prior studies on the role of NKG2D–NKG2D
interactions in the induction of CD8þ antigen-speciﬁc antitumor
responses are mixed. Diefenbach et al. [8] found that the ectopic
expression of NKG2D ligands on tumor cells reduced tumor-
igenicity and led to the induction of antigen-speciﬁc, CD8þ T cell
antitumor immunity. Similar to our results, Cerwenka et al. found
that the forced expression of NKG2D ligands on tumor cells re-
duced tumorigenicity, but did not enhance the generation of tu-
mor-speciﬁc CD8þ T cell responses [3].
We hypothesize that MCA-205-OVA tumor cells induce a
greater OVA-speciﬁc CD8þ T cell response than MCA-205-E1A-
OVA cells due to increased tumor antigen load. The number of
MCA-205-OVA cells used for these studies is well above the TPD50,
which would result in persistent and growing MCA-205-OVA tu-
mor cells in vivo. Conversely, MCA-205-E1A-OVA cells are non-
tumor forming and rapidly eliminated in vivo, which likely leads to
reduced antigen load over the course of the experiment. OT-1 cell
expansion similar to that of MCA-205-OVA cell immunization
were observed with MCA-205-E1A-OVA cells when the number of
cells inoculated was increased 10-fold, (data not shown), sug-
gesting the amount of tumor antigen load may be responsible for
the differences observed between MCA-205-OVA and MCA-205-
E1A-OVA cells.
The reasons for the disparity in the role of NKG2D–NKG2D
interactions in the elicitation of tumor-speciﬁc CD8þ T cell re-
sponses is unclear. It is possible that NKG2D signaling was dis-
pensable in our model due to the presence of a strong foreign
antigen, OVA. Natural tumor antigens may provide weaker acti-
vation signals than OVA, and therefore may require additional co-
stimulation which could be provided by NKG2D signaling. MCA-
205 is mildly immunogenic and therefore expresses an en-
dogenous tumor antigen [23]. However, the tumorigenicity of ei-
ther MCA-205 or MCA-205-E1A tumor cells was not increased in
NKG2D sufﬁcient mice compared to wild type mice. Collectively,
these data suggest that in the MCA-205 model, the interaction of
NKG2D with NKG2D ligands is dispensable for the anti-tumor
immune response.
Finally, studies reported herein suggest that the reduction of
tumorigenicity by E1A is largely independent of NKG2D–NKG2D
ligand interactions in WT B6 mice. Previous work by our labora-
tory has shown that the rejection of tumor cells that express E1A
in WT B6 mice is partially dependent on T cells. In RAG / B6
mice, blocking the interaction of NKG2D with NKG2D ligands in-
creased the tumorigenicity of MCA-205-E1A cells [7]. Because the
expansion of antigen-speciﬁc CD8þ T cells occurs in an NKG2D–
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that there is a redundant role for NK cells in WT B6 mice that is
fulﬁlled by T cells in an NKG2D-independent manner.
Technical issues intrinsic to the MCA-205 model may con-
tribute to the inability to detect a change in tumorigenicity in a
WT B6 mice compared to B6 mice lacking NKG2D. Injection of
MCA-205-E1A cells or MCA-205-E1A-OVA cells fail to cause tumor
formation in a WT animal at the highest challenge dose (107 tumor
cells), which is the highest inoculum we can give in a small vo-
lume, due to technical limitations. Thus, with a higher tumor cell
burden, NKG2D dependent and independent mechanisms may be
required for rejection of MCA-205 tumor cells that express E1A in
WT B6 mice. This hypothesis is consistent with results demon-
strating that that ectopic expression of NKG2D ligands on tumor
cell lines reduces tumorigenicity [3,6–8]. Further investigations on
the role of NKG2D–NKG2D ligand interactions in the reduction of
tumorigenicity by E1A are needed to clarify this issue.
We found the ability of E1A to sensitize cells to NK cell medi-
ated killing is largely NKG2D–NKG2D ligand dependent. In con-
trast, the interaction of NKG2D ligands with NKG2D appears to be
dispensable for the ability of E1A to generate antigen speciﬁc
CD8þ anti-tumor immune responses, and for the reduction of
tumorigenicity in WT B6 mice. These ﬁndings are consistent with
our previous work that showed that E1A may reduce tumor-
igenicity by modulation of tumor microenvironment through the
inhibition of arginase 1 produced by tumor associated macro-
phages [16]. Arginase 1 produced in the tumor microenvironment
results in a depletion of L-arginine, which is essential for T cell
effector function [18]. Additional potential mechanisms whereby
E1A may decrease tumorigenicity include sensitizing cells to im-
mune effector molecules such as TNF-α, TRAIL, nitric oxide, per-
forin and fas-dependent killing [19–22].
In summary, we found that the ability of E1A to reduce the
tumorigenicity of MCA-205 cells and elicit an antigen-speciﬁc CD8
T cell response is independent of the interaction of NKG2D ligands
with NKG2D.4. Materials and methods
4.1. Mice
WT C57BL6/J (B6), B6.129S7-Rag1tm1Mom/J (RAG /), B6.SJL-
Ptprca Pepcb/BoyJ (CD45.1) and C57BL/6-Tg(TcraTcrb)1100Mjb/J
(OT-1) mice were purchased from the Jackson Laboratories. OT-1
mice express a transgene for a T cell receptor that recognizes
ovalbumin (OVA) residues 257–264 in the context of H-2Kb. B6-
Klrk1tm1Dhr (NKG2D /) mice were kindly provided by David H.
Raulet [15] (University of California, Berkeley, Berkeley, CA).
NKG2D / mice were bred with CD45.1þ OT-1þ RAG / mice to
generate NKG2D /CD45.1þ OT-1þ RAG / mice. All animal
work was reviewed and approved by the Medical College of
Wisconsin Institutional Animal Care and Use Committee.
4.2. Reagents
Roswell Park Memorial Institute (RPMI) medium with 5% Fetal
Bovine Serum (FBS) (RPMI-5) or 10% FBS (RPMI-10) supplemented
with Glutamax, glucose and antibiotics was used for all cell cul-
ture. FBS (Atlanta Biologicals) was heat inactivated for 45 min at
56 °C.
4.3. Flow cytometry
Flow cytometry was performed with an LSR II (BD biosciences)
using BD FACSDiva software. Flow cytometry analysis wasperformed using FlowJo software (Tree Star). Antibodies speciﬁc to
mouse CD3 (145-2C11) Alexa Fluor 488 (AF-488); Fluorescein
(FITC), CD8α (5H-10) PE; Paciﬁc Orange (PO), and CD45.1 (A20)
Allophycocyanin (APC) were purchased from Biolegend. Pan-RAE1
(CX1) PE antibody was purchased from BD Biosciences.
4.4. Cell lines
MCA-205, a C57BL/6 derived ﬁbrosarcoma cell line, was kindly
provided by N. Restifo (National Cancer Institute, National In-
stitutes of Health, Bethesda, MD). MCA-205 lines that stably ex-
pressed E1A–OVA (MCA-205-E1A-OVA), or OVA (MCA-205-OVA)
were generated as previously described [16].
4.5. NK cell cytolysis assays
Mouse NK cells were enriched from either B6 or NKG2D deﬁ-
cient splenocytes by nylon wool enrichment as previously de-
scribed [17] and used in a standard 5 h 51Cr release assay [7]. NK
purity was conﬁrmed by ﬂow cytometry, and only NK cell pre-
parations with greater than 90% NK cells were used.
4.6. Quantiﬁcation of OVA speciﬁc CD8 þT cells
OT-1 transgenic CD8þ T cells were harvested from the spleens
of either NKG2Dþ /þCD45.1þ OT-1þ RAG/ mice or
NKG2D /CD45.1þ OT-1þ RAG/ mice. 1105
NKG2Dþ /þCD45.1þ OT-1þ cells or NKG2D/CD45.1þ OT-1þ
cells were adoptively transferred via retro-orbital injection into
WT or NKG2D / B6 mice respectively. The following day, mice
were immunized with 1105 live MCA-205-OVA or MCA-205-
E1A-OVA cells subcutaneously (s.c.) in the hock (the lateral tarsal
region just above the ankle). Five days after tumor cell injection,
the popliteal lymph nodes were removed from WT or NKG2D /
B6 mice and the CD45.1þ OT-I cells were quantitated by ﬂow cy-
tometry by staining for CD45.1þ CD3þ CD8þ T cells. The absolute
number of CD8þ T cells was determined by multiplying the per-
centage of the target cell population by the total number of cells in
the lymph node.
4.7. Tumor induction studies
Quantitative tumor inductions studies were performed as
previously described [7]. Brieﬂy, B6 or NKG2D deﬁcient mice were
administered serial log dilutions of MCA-205 or MCA-205-E1A
tumor cells s.c. in a total volume of 0.2 cc in the ﬂank of WT B6 or
NKG2D and then monitored for tumor growth. Animals were eu-
thanized when tumors reached 20 mm in diameter, or at the end
of a 12-week monitoring period. Tumor producing dose 50 (TPD50)
values, which are the log10 of the number of cells required to form
tumors, were calculated using the Spearman–Karber Formula. Due
to technical limitations, 107 was the highest number of tumor cells
that could be given in 0.2 cc volume. Therefore, if tumors did not
occur at 107 tumor cells, the TPD50 was estimated 0.5 logs higher
than the highest attainable dose (e.g. TPD50¼7.5).
4.8. Statistics
Statistical differences between groups were calculated using
the ANOVA and Dunnett multiple comparison tests. Mann–Whit-
ney tests were used to compare two sets of data. Any p values less
than 0.05 were considered signiﬁcant. Unless otherwise stated, all
data are presented as mean7standard error of mean (SEM). Sta-
tistical analysis was done using Prism version 5.0a software
(GraphPad Software) (*, po0.05; **, po0.01; ***, po0.001).
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